Stem cell factor inhibitor

Patent metadata

Field	Value
Publication number	US-2022017613-A1
Application number	US-202117493411-A
Country	US
Kind code	A1
Filing date	Oct 4, 2021
Priority date	Jan 10, 2011
Publication date	Jan 20, 2022
Grant date	—

Abstract

Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.

First claim

We claim:

1 . A method of treating a fibrotic or tissue remodeling disease comprising administering a therapeutically effective amount of a stem cell factor inhibitor to a subject with or at risk for a fibrotic or tissue remodeling disease.

2 . The method of claim 1 , wherein the inhibitor is an isolated antibody or antigen-binding fragment thereof.

3 . The method of claim 2 , wherein the antibody is a monoclonal antibody or antigen-binding fragment thereof.

4 . The method of claim 2 , wherein the antibody or antigen-binding fragment thereof specifically binds to stem cell factor.

5 . The method of claim 2 , wherein the antibody or antigen-binding fragment thereof specifically binds to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 8.

6 . The method of claim 1 , wherein the inhibitor is a small interfering RNA.

7 . The method of claim 1 , wherein the subject has an abnormal activity of stem cell factor or abnormal collagen production.

8 . The method of claim 1 , wherein the disease is fibrosis, a remodeling disease, or a pulmonary disease.

9 . The method of claim 1 , wherein the disease is idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, acute respiratory distress syndrome, cystic fibrosis, peribronchial fibrosis, hypersensitivity pneumonitis, asthma, sclerodoma, inflammation, liver cirrhosis, renal fibrosis, parenchymal fibrosis, endomyocardial fibrosis, mediastinal fibrosis, nodular subepidermal fibrosis, fibrous histiocytoma, fibrothorax, hepatic fibrosis, fibromyalgia, gingival fibrosis, or radiation-induced fibrosis.

10 . The method of claim 2 , wherein the antibody or antigen-binding fragment thereof is delivered into an airway of the subject by intranasal administration.

11 . The method of claim 1 , wherein said administering the inhibitor reduces an activity of a receptor and/or reduces an interaction of stem cell factor with a receptor.

12 . The method of claim 11 , wherein the receptor is a receptor tyrosine kinase.

13 . The method of claim 11 , wherein the receptor is c-Kit.

14 . The method of claim 1 , wherein administering the inhibitor to a subject results in a direct inhibition of fibroblast activation.

15 . A composition comprising an isolated antibody or antigen-binding fragment thereof that specifically binds to stem cell factor.

16 . The composition of claim 15 wherein the isolated antibody or antigen-binding fragment thereof specifically binds to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 8.

17 . The composition of claim 15 wherein the antibody is a monoclonal antibody or antigen-binding fragment thereof or the antibody is a humanized antibody or antigen-binding fragment thereof.

18 . A method comprising the steps of providing an inhibitor of stem cell factor and administering the inhibitor to a cell or tissue.

Assignees

• Univ Michigan Regents

Inventors

• Lukacs Nicholas W
• Dolgachev Vladislav A
• Kunkel Steven L
• Hogaboam Cory M
• Phan Sem H

Classifications

• C07K16/22 Primary

  against growth factors {; against growth regulators} · CPC title

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• A61P13/12

  of the kidneys · CPC title